Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

PCV10 Reactogenicity and Immunogenicity Study - Malindi (PRISM)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Kenya Ministry of Health
University of Oxford
University of Colorado, Denver
GlaxoSmithKline
Information provided by (Responsible Party):
KEMRI-Wellcome Trust Collaborative Research Program
ClinicalTrials.gov Identifier:
NCT01028326
First received: December 7, 2009
Last updated: December 4, 2015
Last verified: December 2015